| pubmed-article:6609192 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C0003315 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C0206431 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C0041625 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C1823153 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C2349976 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C1552644 | lld:lifeskim |
| pubmed-article:6609192 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:6609192 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:6609192 | pubmed:dateCreated | 1984-6-1 | lld:pubmed |
| pubmed-article:6609192 | pubmed:abstractText | Murine low-density spleen cells have potent antigen-presenting ability in a hapten-specific cytolytic T lymphocyte (CTL) system using the hapten azobenzenearsonate (ABA). Exposure of these cells to 0.33 KJ/m2 of ultraviolet radiation (UVR) after coupling to hapten results in markedly inhibited antigen-presenting function that can be substantially corrected or bypassed by interleukin 1 (IL 1). These results have been interpreted to reflect an inhibition of Lyt-1+ T cell activation by UVR-treated APC. Treatment of these cells sequentially with 1500 rad of gamma-radiation (GR) prior to hapten coupling, followed by 0.33 KJ/m2 of UVR radiation after coupling, results in an antigen-presenting defect only minimally improved by IL 1. However, partially purified interleukin 2 (IL 2) can completely bypass or correct this defect. Thus, combined GR and UVR induces a different or more profound defect in APC function when compared to UVR alone. However, these cells do provide a signal(s) other than hapten necessary for CTL activation because ABA-coupled high density spleen cells do not activate CTL cells, even with the addition of IL 2. Fluorescence-activated cell sorter analysis demonstrates that exposure of these low density spleen cells to GR or UVR results in decreased I-A antigen expression at 24 hr than either alone. The addition of nonhapten-coupled low-density APC partially reconstitutes the ability of combined GR/UVR-treated LD-APC to present antigen, and this effect is enhanced by the administration of exogenous IL 1. This occurs despite a lack of significant accessory cell activity by the LD-APC for the ABA hapten, and indicates that combined GR/UVR-treatment of APC is not functionally equivalent to completely removing them. | lld:pubmed |
| pubmed-article:6609192 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6609192 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:6609192 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6609192 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6609192 | pubmed:month | May | lld:pubmed |
| pubmed-article:6609192 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:6609192 | pubmed:author | pubmed-author:GreeneM IMI | lld:pubmed |
| pubmed-article:6609192 | pubmed:author | pubmed-author:ParrishJ AJA | lld:pubmed |
| pubmed-article:6609192 | pubmed:author | pubmed-author:MisraH NHN | lld:pubmed |
| pubmed-article:6609192 | pubmed:author | pubmed-author:TominagaAA | lld:pubmed |
| pubmed-article:6609192 | pubmed:author | pubmed-author:GransteinR... | lld:pubmed |
| pubmed-article:6609192 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6609192 | pubmed:volume | 132 | lld:pubmed |
| pubmed-article:6609192 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6609192 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6609192 | pubmed:pagination | 2210-7 | lld:pubmed |
| pubmed-article:6609192 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:meshHeading | pubmed-meshheading:6609192-... | lld:pubmed |
| pubmed-article:6609192 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6609192 | pubmed:articleTitle | Molecular signals in antigen presentation. II. Activation of cytolytic cells in vitro after ultraviolet radiation or combined gamma and ultraviolet radiation treatment of antigen-presenting cells. | lld:pubmed |
| pubmed-article:6609192 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6609192 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:6609192 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:6609192 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6609192 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6609192 | lld:pubmed |
